MPTP induced Pakinson model

Acute MPTP-induced Parkinson's disease model: on the first treatment day, mice are treated with physiological saline or test compounds, and 18 h after treatment, experimental animals are injected i.p. with 4x20 mg/kg 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP, Sigma)/sterile physiological saline (0.9% NaCl) every two hours. After treatment, the general condition of the animals is continuously monitored and motor function tests are performed using open field and rotarod tests. 72 h after the last MPTP injection, the experimental animals are anaesthetised with CO2 gas, decapitated with quillotine, exsanguinated and brain tissue samples are collected. The tissues are then used for monoamine content measurement, protein analysis or histological staining.

Subacute MPTP-induced Parkinson's disease model (Tatton-Kish model): In this case, mice are treated with a daily dose of 30 mg/kg i.p. MPTP for 5 days, followed by treatment with test compounds for 21 days (10 mg/day i.p.). After MPTP treatment, the general condition of the animals is continuously monitored. At the end of the experiment, the experimental animals are anaesthetized with CO2 gas, decapitated with quillotine, exsanguinated and tissue samples from the brain are collected. The tissue samples are then used for monoamine content measurement, protein analysis or histological staining.